Genscript Biotech Corporation
1548
Rank in Stocks
#2097
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Share Price
$4.37
Market Cap
$9.84B
Change (1 day)
2.30%
Change (1 year)
109.57%
Country
HK
Trade Genscript Biotech Corporation (1548)
Category
Healthcare
Revenue for Genscript Biotech Corporation (1548)
Revenue in Jun 2026 TTM: $844.00M
According to Genscript Biotech Corporation latest financial reports the company's current revenue (TTM) is $844.00M. In 2023 the company made a revenue of $839.53M an increase over the revenue in the year 2022 that was $625.70M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Genscript Biotech Corporation from 2013 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $844.00M | 41.97% |
| 2024 | $594.49M | -29.19% |
| 2023 | $839.53M | 34.17% |
| 2022 | $625.70M | 27.67% |
| 2021 | $490.10M | 25.39% |
| 2020 | $390.85M | 42.98% |
| 2019 | $273.35M | 18.33% |
| 2018 | $231.02M | 51.34% |
| 2017 | $152.65M | 33.04% |
| 2016 | $114.74M | 32.32% |
| 2015 | $86.71M | 23.88% |
| 2014 | $69.99M | 16.45% |
| 2013 | $60.10M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 1,395.77% |
US
|
|
| $2.23B | 163.98% |
US
|
|
| $15.74B | 1,765.44% |
AU
|
|
| $6.02B | 613.42% |
NL
|
|
| - | - |
CH
|
